THELIN TABLET

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

SITAXSENTAN SODIUM

Disponible des:

PFIZER CANADA ULC

Codi ATC:

C02KX03

Designació comuna internacional (DCI):

SITAXENTAN

Dosis:

100MG

formulario farmacéutico:

TABLET

Composición:

SITAXSENTAN SODIUM 100MG

Vía de administración:

ORAL

Unidades en paquete:

28

tipo de receta:

Prescription

Área terapéutica:

MISCELLANEOUS VASODILATATING AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0152215001; AHFS:

Estat d'Autorització:

CANCELLED POST MARKET

Data d'autorització:

2011-04-30

Fitxa tècnica

_ _
_ _
_PR_
_THELIN_
_® _
_(sitaxsentan sodium tablets) Product Monograph _
_Page 1 of 28_
PRODUCT MONOGRAPH
PR
THELIN
®
(sitaxsentan sodium tablets)
100 mg
Endothelin receptor antagonist
® Registered trademark of Encysive Pharmaceuticals Inc.
Pfizer Canada Inc.
17 300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of preparation:
April 26, 2010
Submission Control Number: 134705
_ _
_ _
_PR_
_THELIN_
_® _
_(sitaxsentan sodium tablets) Product Monograph _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................... 3
SUMMARY OF PRODUCT INFORMATION
............................................................. 3
INDICATIONS AND CLINICAL
USE.........................................................................
3
CONTRAINDICATIONS
..............................................................................................
3
DOSAGE AND
ADMINISTRATION.........................................................................
13
OVERDOSAGE:
..........................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
....................................................... 15
STORAGE AND
STABILITY.....................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 16
PART II: SCIENTIFIC
INFORMATION........................................................................
18
PHARMACEUTICAL
INFORMATION.....................................................................
18
CLINICAL
TRIALS.....................................................................................................
19
DETAILED
PHARMACOLOGY................................................................................
21
TOXICOLOGY
............................................................................................................
24
REFERENCES
.................................................................